
Taipei – The R&D team at Taiwan’s EG BioMed Co. Ltd. has made significant progress in the field of pancreatic cancer detection, with their newly developed EG-Pancreatic Blood Test-E1 technology receiving high acclaim from international experts. The technology was featured in the online conference journal of the American Society of Clinical Oncology (ASCO), marking a breakthrough for Taiwanese technology in the global medical field.
The team has been researching DNA cancer detection technology at Taiwan’s top universities since 2016 and has published their findings in several internationally renowned journals. This series of research has been supported by Taiwan’s Ministry of Science and Technology and Taipei Medical University, and has won the Taiwan National Innovation Award and the Future Tech Breakthrough Award.
EG BioMed has published over eight research papers on the blood cancer detection and its clinical application of circulating methylated cell-free DNA (cfDNA) across various cancer types from 2018 to 2024. Additionally, EG BioMed has secured patents for blood tests targeting breast cancer in both Taiwan and Europe, as well as for colorectal cancer in Taiwan. Currently, patent applications for blood tests in breast, colorectal, pancreatic, and lung cancer are under review in multiple countries including the US, Europe, Australia, Japan, Korea, Singapore, Malaysia, China, and Taiwan.

In terms of the patent application for blood tests targeting pancreatic cancer, a provisional application was submitted on February 17, 2023, with application number 63/485,748. The US Patent application number is 18/444,053, filed on February 16, 2024. Additionally, a Global PCT application was submitted on February 16, 2024, with the application number, PCT/AU2024/050116.
The EG-Pancreatic Blood Test-E1 utilizes cfDNA analysis technology and does not require the current clinical CA19-9 blood test, achieving over 99% sensitivity and more than 90% accuracy when used alone. This technology can be transported and stored at room temperature for up to 14 days and has passed a comprehensive analysis of 450,000 methylation sites for cancer-specific genes, greatly simplifying the testing process for users.
EG BioMed sets itself apart with a cfDNA methylation and qPCR-based analysis technique, known for its exceptional stability, sensitivity, and accuracy. This method not only reduces processing times but also streamlines laboratory workflows. In contrast to methods that rely on fragile RNA for microRNA analysis, EG BioMed’s approach provides greater resilience and durability. Additionally, while some competitors employ NGS technology for all genomic analysis, involving complex procedures, this often results in decreased data repeatability, longer reporting times, and higher costs.
EG BioMed’s technological achievements not only highlight Taiwan’s leading position in the global medical technology field but also provide a possibility for early diagnosis for pancreatic cancer patients, thereby improving their treatment outcomes and quality of life. The successful application of this technology will aid in the early detection and treatment of pancreatic cancer, avoiding missed treatment opportunities due to late diagnosis.
About EG BioMed
EG BioMed Co. Ltd. is a biomedical company dedicated to developing innovative medical diagnostic technologies, known for its high sensitivity and accuracy in cancer detection. The company continues to push the frontier of medical technology with the aim of improving patients’ lives through technological innovation.
Comentários